Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Aortic and coronary atherosclerosis were studied in subjects with a malignant disease and compared with those in the three atherosclerosis reference groups. In general, subjects with a malignant disease had little atherosclerosis, except for men with lung or prostatic cancer; in particular, men with lung cancer tended to have more extensive aortic atherosclerosis. Atherosclerosis was less extensive in subjects with tumours specific to females. The ratios between the different types of lesions was preserved and the change was therefore quantitative rather than qualitative. No proof of a real negative influence on atherosclerosis by malignant diseases was found but wasting could be one factor influencing the development of atherosclerosis in tumour subjects. Such subjects, except those with lung and prostatic cancer, could have been included in the low atherosclerosis group which was an index of the mean basic level of atherosclerosis in the populations studied.
 ...
PMID:Atherosclerosis and malignant tumours. 108 95

In 17 prostatic cancer patients, changes in the plasma lipoprotein pattern, including high density lipoprotein (HDL) subfractions, and in glucose tolerance were compared after 6 months on parenteral polyestradiol phosphate (PEP; Estradurin, 80 or 160 mg/month) with the respective changes in orchiectomized patients. In the estrogen group there was no change in the total serum cholesterol level, whereas in the orchiectomy group an increase of 10% was observed. Estrogen therapy resulted in a significant increase of serum HDL (11%) and HDL2 cholesterol (26%) levels; in the orchiectomy group these fractions remained unchanged. Estrogen therapy induced a significant decrease in total serum triglycerides (24%) and in low density lipoprotein triglycerides (27%); in the orchiectomy group reverse changes were observed. PEP treatment caused changes in the serum lipoprotein pattern, which apparently decreases the risk of atherosclerosis.
 ...
PMID:Effects of orchiectomy and polyestradiol phosphate therapy on serum lipoprotein lipids and glucose tolerance in prostatic cancer patients. 235 Nov 92

One hundred consecutive patients aged up to 75 with newly diagnosed cancer of the prostate suitable for hormonal treatment were included in a controlled study of the cardiovascular effects of oestrogen versus orchidectomy. In all cases pre-existing cardiovascular morbidity was excluded. Of the 100 patients, 91 were strictly randomised to receive either oestrogen (n = 47) or orchidectomy (n = 44) and 9 (6 given oestrogen, 3 orchidectomy) either chose their own treatment (five cases) or had it selected for them by the urologist (four). Oestrogen was given in the lowest recommended dosage in Sweden--namely, as 160 mg polyestradiol phosphate intramuscularly every month for the first three months, then 80 mg monthly, plus ethinyloestradiol 1 mg by mouth daily for the first two weeks, then 150 micrograms daily. At entry to the study the two treatment groups showed no difference in demographic characteristics or conventional risk factors for cardiovascular disease. During the first year, however, 13 (25%) of the patients given oestrogen suffered major cardiovascular events as compared with none of the patients after orchidectomy. Patients in the oestrogen treatment group who did not have minor signs of atherosclerosis at entry to the study suffered a similar incidence of cardiovascular complications to those who did have these signs at entry. The substantially increased risk of cardiovascular complications in patients given oestrogen for prostatic cancer warrants careful consideration when choosing treatment for this disorder.
 ...
PMID:Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects. 309 Nov 38

The authors made a randomized prospective study of estrogen therapy versus orchidectomy in patients with prostatic cancer (n = 100, Huddinge Hospital, Sweden) to investigate the possibility of predicting cardiovascular events during hormonal treatment. Patients with preexisting cardiovascular morbidity were excluded (16%). Prior to the allocation of therapy, the following were performed: exercise stress test; physiologic evaluation of the peripheral circulation; blood volume estimation; chest x-ray; blood tests, including hormones, lipoproteins, and antithrombin III; and a physical examination and history by a cardiologist. Thirteen (25%) of the patients given estrogen therapy (n = 53) had cardiovascular complications during the first year of treatment compared with none in the orchidectomy group. The authors made a multivariate discriminant analysis of the pretreatment examinations of the estrogen-treated patients; this resulted in a discriminant function including S-T segment depression in lead CH2 during the exercise stress test and blood tests for cholesterol, follicle-stimulating hormone, and luteinizing hormone. This function correctly classified 84% of the estrogen-treated patients as patients with or without risk of a cardiovascular complication. Briefly stated, if patients with prostatic cancer are examined by means of exercise stress tests and blood tests for luteinizing hormone, cholesterol, and follicle-stimulating hormone prior to treatment, the discriminant function enables the authors to identify an extremely high-risk group for cardiovascular complications if estrogen therapy is commenced. The strong association of an increased luteinizing hormone with cardiovascular complications during estrogen treatment makes it mandatory to investigate its role in the pathogenesis of atherosclerosis and cardiovascular events.
 ...
PMID:Prediction of cardiovascular complications in patients with prostatic cancer treated with estrogen. 357 55

The incidence of cardiovascular disease is lower in women than in men, but is raised in men with prostatic cancer treated with estrogens. Changes of the plasma lipoproteins are related to the development of ischaemic cardiovascular disease and can be brought about by hormonal treatment. We have therefore studied plasma lipoproteins during estrogen treatment and after orchidectomy. 16 patients with prostatic carcinoma were treated with ethinyl estradiol daily by mouth and polyestradiol phosphate intramuscularly once a month. 15 other patients were treated by bilateral orchidectomy. Cholesterol (C), triglyceride (TG), and phospholipid (PL) concentrations in plasma and in the very low density (VLDL), low density (LDL) and high density lipoprotein (HDL) fractions were determined before starting treatment and 2 weeks and 8 weeks later. In the estrogen treated group the mean plasma C concentration decreased by 14 and 10%, while the mean HLD-C increased by 23 and 53%, and the mean LDL-C decreased by 24 and 25% at 2 and 8 weeks respectively. The mean PL concentration in HDL increased by 36 and 79% while that in LDL decreased by 12 and 18%. The mean plasma TG concentration was increased by 36 and 46%, mainly reflecting a rise of TG in the HDL-LDL fraction. Orchidectomy created only slight changes of plasma lipids. After 8 weeks the mean C concentration in plasma was raised by 10% and the mean PL concentration by 11%, owing to a 13% rise in the mean HDL-PL level. The changes in plasma lipoprotein pattern created by high doses of estrogens are mainly thought to protect against the development of atherosclerosis. The slight changes that take place after orchidectomy can hardly affect the incidence of cardiovascular disease.
 ...
PMID:Plasma lipoproteins during anti-androgen treatment by estrogens or orchidectomy in men with prostatic carcinoma. 726 28

Family physicians should be aware of the potential effects and complications of vasectomy so they can appropriately counsel patients seeking sterilization. Vasectomy produces anatomic, hormonal and immunologic changes and, although not substantiated by clinical studies, has been reputed to be associated with atherosclerosis, prostate cancer, testicular cancer and urolithiasis. Complications of vasectomy include overt failure, occasional sperm in the ejaculate, hematoma, bleeding, infection, sperm granuloma, congestive epididymitis, antisperm antibody formation and psychogenic impotence. Compared with tubal ligation, vasectomy has fewer serious complications and a comparable failure rate.
 ...
PMID:Complications of vasectomy. 823 40

About 42 million couples worldwide, most of whom live in developing countries, have chosen vasectomy as their family planning (FP) method. There has been considerable research on the short and longterm safety of vasectomy. In the 1970s, research on rhesus monkeys indicated an increased risk of atherosclerosis, possible due to an increased level of antisperm antibodies. Later research on vasectomized men in developed and developing countries did not support these animal studies. Epidemiological studies in the US and Scotland showed an increased risk of testicular cancer in vasectomized men. A WHO meeting reviewed these studies and found no logical mechanism for this association. Later research found that vasectomy does not cause testicular tumors or accelerate the development of existing neoplasms. 2 studies in the US in 1990 suggested that vasectomy increases the risk of prostate cancer many years after the procedure. No studies since then have substantiated these findings. Besides, no known biological mechanism or hypothesis can explain the association. Vasectomy and prostate cancer specialists at a meeting of the US National Institutes of Health in March, 1993, agreed that physicians should continue to perform vasectomies and need not change clinical practice. Extrapolation of the US results to other countries is not logical, particularly to countries where prostate cancer is rare. Nevertheless, these recent reports will probably affect FP programs and acceptance of vasectomy in countries where vasectomy is common. Still, the evidence does not justify changes pertaining to vasectomy in national FP programs. Research on the longterm safety of vasectomy should be conducted. In conclusion, vasectomy is still a simple, safe, and very effective FP method.
 ...
PMID:The safety of vasectomy: recent concerns. 832 61

New Zealand had the highest prevalence of vasectomy in the world. A national survey conducted over the period 1983-86 found that 23% of married women aged 25-44 relied upon their husbands' vasectomies for contraception, while only 19% relied upon tubal ligation. It seems that in no other country male sterilization is more common than female sterilization. Vasectomy seems to be at least as effective as tubal ligation and is even less commonly followed by significant complications, despite unfounded scares over time about potential associations with the decreased production of testicular hormone, atherosclerosis, and testicular cancer. There is, however, current cause for concern that vasectomies potentially increase the risk of prostate cancer. Studies have shown the relative risk of prostate cancer to increase with the number of years since vasectomy. One may attribute these findings to chance, bias, confounding, or a causal relationship, with the first two factors being less likely. We have a poor understanding of the genesis of prostate cancer. The World Health Organization convened a meeting in October 1991 to review the existing biological and epidemiological evidence for any such relationship. The organization recommended future research, but concluded that a causal relationship between vasectomy and risk of prostate cancer appeared unlikely and that changes to family planning policies were unwarranted. In New Zealand, however, where the prevalence of cancer before age 75; 400 men die annually. This high rate of mortality has increased in recent decades. Even though the verdict is still out on the link between vasectomy and prostate cancer, New Zealand doctors should be informing candidates for vasectomy about the possible link with prostate cancer, as well as about the risks and benefits of other contraceptive methods.
 ...
PMID:Vasectomy and prostate cancer: is there a link? 833 90

Prostatic Intraepithelial Neoplasia (PIN) and prostatic cancer (PCA) are not caused by infection, allergic reaction, inadequate immunological response, ischemia, ageing, systemic hormones, carcinogens, nor prostatic ductal contents. PIN and PCA are apparently caused by increased inner acinar pressure due to partially blocked draining ducts. Only this explanation can account for all the observations about PIN and PCA. All other possible causes are disproved by specific observations. In order to further clarify the cause of PIN and PCA, it is important to discover if peripheral zone lesions cluster around ducts or blood vessels. PIN patterns are the morphological precursors of both PCA and prostatic cysts. Different PIN patterns represent different adaptive stages to increasing inner acinar pressure. The immediate tissue cause of PCA is PIN disruption seeding the stroma with high-grade PIN (HGPIN) cells. These cells, programmed for adaptive proliferation and mobility in PIN, are sufficient in the stroma to cause all stages and patterns of invasive PCA. No mutated cells are necessary. For reasons given, the primary cause of the initial ductal blockage that results in PIN and PCA cannot be inflammation, stones, proteineous plugs, infarction, venus thrombosis, ductal hyperplasia, nor a constricted penis at ejaculation. Only benign prostatic hyperplasia (BPH) can explain all the facts and is thus the primary cause of the ductal blockage resulting in cysts, PIN and PCA. The main causes of BPH are apparently disuse atrophy of sexual and abdominal muscles, and atherosclerosis of the capsular branch of the prostatic artery, causes atypical adenomatous hyperplasia (AAH) in the transition zone. The resulting muscular and glandular atrophy decreases local and general growth inhibitors. New growth in the adult prostate is abnormal because epithelial cells grow into ducts rather into the stroma. In such ducts, the growths cannot receive stromal growth inhibitory signals, and thus continue to grow indefinitely and result in BPH, AAH-adenosis, blockage of ducts, cysts, PIN and PCA.
 ...
PMID:A unifying hypothesis that links benign prostatic hyperplasia and prostatic intraepithelial neoplasia with prostate cancer. Invited comments. 860 75

Incidences of breast, colorectal and prostate cancer are high in the Western world compared to countries in Asia. We have postulated that the Western diet compared to the semivegetarian diet in some Asian countries may alter hormone production, metabolism or action at the cellular level by some biochemical mechanisms. Our interest has been focused on two groups of hormone-like diphenolic phyto-oestrogens of dietary origin, the lignans and isoflavonoids abundant in plasma of subjects living in areas with low cancer incidence. The precursors of the biologically active compounds detected in man are found in soybean products, whole-grain cereal food, seeds, and berries. The plant lignan and isoflavonoid glycosides are converted by intestinal bacteria to hormone-like compounds. The weakly oestrogenic diphenols formed influence sex-hormone production, metabolism and biological activity, intracellular enzymes, protein synthesis, growth factor action, malignant cell proliferation, differentiation, cell adhesion and angiogenesis in such a way as to make them strong candidates for a role as natural cancer-protective compounds. Their effect on some of the most important steroid biosynthetic enzymes may result in beneficial modulation of hormone concentrations and action in the cells preventing development of cancer. Owing to their oestrogenic activity they reduce hot flushes and vaginal dryness in postmenopausal women and may to some degree inhibit osteoporosis, but alone they may be insufficient for complete protection. Soy intake prevents oxidation of the low-density lipoproteins in vitro when isolated from soy-treated individuals and affect favourably plasma lipid concentrations. Animal experiments provide evidence suggesting that both lignans and isoflavonoids may prevent the development of cancer as well as atherosclerosis. However, in some of these experiments it has not been possible to separate the phyto-oestrogen effect from the effect of other components in the food. The isoflavonoids and lignans may play a significant inhibitory role in cancer development particularly in the promotional phase of the disease, but recent evidence points also to a role in the initiation stage of carcinogenesis. At present, however, no definite recommendations can be made as to the dietary amounts needed for prevention of disease. This review deals with all the above-mentioned aspects of phyto-oestrogens.
 ...
PMID:Phyto-oestrogens and Western diseases. 918 25


1 2 3 4 5 6 7 8 Next >>